Athersys is a clinical stage biopharmaceutical company with a growing pipeline of highly differentiated, potential best in class therapeutics to treat significant and life-threatening diseases. We are engaged in the discovery and development of innovative new medicines designed to extend and enhance the quality of human life. Through the application of our proprietary technologies, we have established a pipeline of therapeutic product development programs in multiple disease areas. This pipeline includes both stem cell therapy and pharmaceuticals.
Cleveland, US
60 (est)+6%
Athersys was founded in 1995 and is headquartered in Cleveland, US

Key People at Athersys

Gil Van Bokkelen

Gil Van Bokkelen

Chairman & CEO
William Lehmann Jr

William Lehmann Jr

President, COO
John Harrington

John Harrington

Executive Vice President and Chief Scientific Officer
Robert Deans

Robert Deans

Executive Vice President, Regenerative Medicine
Laura Campbell

Laura Campbell

Manal Morsy

Manal Morsy

Vice President, Global Regulatory Affairs

Athersys Locations

Cleveland, US
Canton, US

Athersys Metrics

Athersys Summary

Market capitalization

$129 M

Closing share price

Athersys's current market capitalization is $129 M.

Athersys Financials

Athersys's revenue is $11.9 M in FY, 2015 which is 636.17% increase from the previous period.
FY, 2013FY, 2014FY, 2015


$2.44 M$1.62 M$11.9 M

Operating income

$-24.5 M$-29 M$-17.2 M

Net Income

$-30.7 M$-22.1 M$-16.4 M

Operating cash flow

$6.42 M$-5.82 M$-3.1 M

    Athersys Market Value History

    We estimate that Athersys's current employees are approximately 18% female and 82% male.

    Athersys Online Presence

    Athersys Company Life

    You may also be interested in